ALLO
AllogeneยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ALLO Profile
Allogene Therapeutics, Inc.
A company that developing genetically engineered allogeneic T cell therapies for cancer
Biological Technology
11/30/2017
10/11/2018
NASDAQ Stock Exchange
226
12-31
Common stock
210 East Grand Avenue, South San Francisco, California 94080
--
Allogene Therapeutics, Inc., was incorporated in Delaware on November 30, 2017 and is headquartered in South San Francisco, California. The company is a clinical-stage immuno-oncology company that has pioneered the development and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of cancer. The Company is developing a line of off-the-shelf T cell product candidates designed to target and kill cancer cells. Allogene Therapeutics, Inc .'s engineered T cells are allogeneic, which means that they come from a healthy donor and are used in any patient, not in the case of an individual patient from a patient, such as autologous T cells.
